Non-alcoholic fatty liver disease through the female lifespan: the role of sex hormones
- 18 March 2022
- journal article
- review article
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 45 (9) , 1609-1623
Abstract
The prevalence of non-alcoholic fatty liver disease (NAFLD) differs between various stages of the female lifespan. The aim of this review is to summarize current evidence on the association of NAFLD and circulating sex hormones and to explore the pathogenesis of NAFLD within the context of (1) sex hormone changes during the reproductive, post-reproductive female life and beyond and (2) the in vitro and in vivo evidence on pharmacological modulation in women on menopausal hormone treatment (MHT) or endocrine therapy after breast cancer. The fluctuation in estrogen concentrations, the relative androgen excess, and the age-related reduction in sex hormone-binding globulin are related to increased NAFLD risk. Moreover, the peri-menopausal changes in body composition and insulin resistance might contribute to the increased NAFLD risk. Whether MHT prevents or improves NAFLD in this population remains an open question. Studies in women with breast cancer treated with tamoxifen or non-steroidal aromatase inhibitors point to their adverse effects on NAFLD development, although a more pronounced effect of tamoxifen is reported. Future studies focusing on the underlying pathogenesis should identify subgroups with the highest risk of NAFLD development and progression into more aggressive forms, as well as elucidate the role of hormone therapies, such as MHT.Keywords
This publication has 95 references indexed in Scilit:
- Associations of Fatty Liver Disease and Other Factors Affecting Serum SHBG Concentrations: A Population Based Study on 1657 SubjectsHormone and Metabolic Research, 2013
- NONALCOHOLIC FATTY LIVER DISEASE IN MENOPAUSAL WOMENArquivos de Gastroenterologia, 2013
- Potential Role of Tumor Necrosis Factor-α in Downregulating Sex Hormone–Binding GlobulinDiabetes, 2012
- Aging is a risk factor of nonalcoholic fatty liver disease in premenopausal womenWorld Journal of Gastroenterology, 2012
- Sex Hormones in Postmenopausal Women Receiving Low‐Dose Hormone Therapy: The Effect of BMIObesity, 2011
- Regional Anthropometric Measures and Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver DiseaseClinical Gastroenterology and Hepatology, 2010
- Menopausal status and hepatic steatosis in a general female populationGut, 2007
- Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical backgroundJournal of Gastroenterology, 2003
- Effects of Tamoxifen on Hepatic Fat Content and the Development of Hepatic Steatosis in Patients with Breast Cancer: High Frequency of Involvement and Rapid Reversal After Completion of Tamoxifen TherapyAmerican Journal of Roentgenology, 2003
- Androgen Activity as a Risk Factor for Impaired Glucose Tolerance in Postmenopausal WomenDiabetes Care, 1996